Rapport Therapeutics reported Q2 2026 financials and announced the initiation of FOCUS 1 and 2 Phase 3 trials for RAP-219. The company maintains strong liquidity expected to fund operations into 2029. Analysis: This clinical advancement represents a significant milestone for the pipeline and validates the underlying science of the lead asset.